November 2004, Volume 34 Number 11 , p 30 - 30
© 2004 Lippincott Williams & Wilkins, Inc. Volume 34(11) November 2004 p 30 Vioxx withdrawn from the market [DRUG NEWS: CARDIOVASCULAR RISKS]
In September, Merck & Co. voluntarily withdrew Vioxx (rofecoxib) from the worldwide market based on data from a large 3-year prospective clinical trial (Adenomatous Polyp Prevention on Vioxx, or APPROVe). Categorized as a selective nonsteroidal anti-inflammatory drug, Vioxx was FDA-approved to relieve pain from osteoarthritis, rheumatoid arthritis, and primary dysmenorrhea.
The APPROVe trial, designed to test the effectiveness of Vioxx in preventing colorectal polyps in patients with a history of colorectal cancer, revealed an increased relative risk of cardiovascular events such as myocardial infarction and stroke beginning after 18 months of treatment. The risk of cardiovascular events wasn't increased during ...